A monthly Internet and Print Media publication featuring:
breaking news and corporate changes with CEO, CFO and Analyst interviews

Cover Story

CEOCFO
Interview
Index &
Quotes

CEOCFO
Current Issue

Future
Features

Monthly
Analyst
Industry
Review

Analyst
Interviews
and Reports

Corporate
Financials

Newsflash!
 
Archived
CEOCFO
Interviews
 
About
CEOCFO
interviews.com

Contact & Ordering

A new generation of Anti-Sense
chemistries…synthetic DNA

Healthcare
Biotechnology & Drugs
OTC: HYBN

Hybridon, Inc.

Stephen R. Seiler
Chief Executive Officer

Interview Conducted by:
Diane Reynolds, Co Publisher

CEOCFOinterviews.com
July 2002

Company Profile:

Hybridon is a leading company in the discovery and development of therapeutic and diagnostic uses of synthetic DNA.  It is synthetic DNA chemistry, which runs through the core of all of our technologies.  More importantly, Hybridon is now in the position to accelerate the transformation of technology into drugs.   We’ve spent the last decade or so since the company’s founding building up our technology base.  We have reached a point now where we can begin the process of transforming our company’s technology into drugs and we are bringing those technologies and drugs to the clinic today.

Interview Highlights::

-           Synthetic DNA.

-           Why it is important.

-           Companys’ transition.

-           Working in combination with other drugs.

-           Shareholder value through clinical development.

-           Added value for the future.

-           Cash/Credit issues.

-           Biggest challenge.

-           Important milestones for investors to consider.

-           International markets.

To receive a copy of this highly informative interview, left click here: Contact & Ordering

disclaimer